ライフサイエンスコーパス: AIDS patient

1 tizing fasciitis in a previously undiagnosed AIDS patient.

2 ression during C. neoformans infection of an AIDS patient.

3 f Kaposi's sarcoma, the most common tumor of AIDS patients.

4 c infections among transplant recipients and AIDS patients.

5 ell as disseminated infection, especially in AIDS patients.

6 cal patients and of oropharyngeal disease in AIDS patients.

7 d microarray assays of 20 fecal samples from AIDS patients.

8 that is the most common tumor affecting HIV/AIDS patients.

9 ections in immunocompromised persons such as AIDS patients.

10 iltration of T lymphocytes has been noted in AIDS patients.

11 heavily drug-experienced and therapy-failed AIDS patients.

12 lesions resembling oral hairy leukoplakia in AIDS patients.

13 ole medical interest range for CD4 counts in AIDS patients.

14 he development of HIV-associated dementia in AIDS patients.

15 ion in immunocompromised individuals such as AIDS patients.

16 re neuronal, astrocyte, and myelin damage in AIDS patients.

17 ay be a reservoir for HIV-1 in the brains of AIDS patients.

18 marrow transplant recipients and cancer and AIDS patients.

19 the most frequent cause of malignancy among AIDS patients.

20 to a variety of vasculopathic conditions in AIDS patients.

21 particular occur at very high frequencies in AIDS patients.

22 es a life-threatening meningoencephalitis in AIDS patients.

23 te to the apoptosis and dementia observed in AIDS patients.

24 se caused by this opportunistic infection of AIDS patients.

25 any mature B cell lymphomas, especially from AIDS patients.

26 o improve thymic function in the majority of AIDS patients.

27 ephalitis, occur with increased frequency in AIDS patients.

28 immunities of HIV-1-infected individuals and AIDS patients.

29 the most common cause of malignancies among AIDS patients.

30 neumonitis in immunodeficient people such as AIDS patients.

31 oencephalitis in a significant percentage of AIDS patients.

32 hat has been used in cachectic hepatitis and AIDS patients.

33 contribute to the lymphocyte dysfunction of AIDS patients.

34 oridium parvum, an opportunistic pathogen of AIDS patients.

35 nimals and cause opportunistic infections in AIDS patients.

36 in immunocompromised humans, particularly in AIDS patients.

37 al patients, and of oropharyngeal disease in AIDS patients.

38 solated HIV-1-producing CD8+ clones from two AIDS patients.

39 ic pathogen of the central nervous system in AIDS patients.

40 e skin and mucosal surfaces and is common in AIDS patients.

41 aneous infection by >1 UL4 type is common in AIDS patients.

42 individuals, including organ transplant and AIDS patients.

43 DS patients were comparable to those for non-AIDS patients.

44 and is among the leading causes of death of AIDS patients.

45 s immunocompromised hosts such as cancer and AIDS patients.

46 d fungal pathogen causing mucosal disease in AIDS patients.

47 tablished in the cachexia seen in cancer and AIDS patients.

48 iterranean, but is rare elsewhere, except in AIDS patients.

49 as other common coinfections encountered by AIDS patients.

50 ost prevalent opportunistic infections among AIDS patients.

51 r the treatment of cerebral toxoplasmosis in AIDS patients.

52 ogressive loss of CD4(+) T cells observed in AIDS patients.

53 for the treatment of P. carinii pneumonia in AIDS patients.

54 protect DC from HIV-induced cytopathicity in AIDS patients.

55 possible source of infection in AIDS and non-AIDS patients.

56 d individuals, such as posttransplant or HIV/AIDS patients.

57 fection resulting in retinitis in 15%-40% of AIDS patients.

58 sensitivity and specificity, particularly in AIDS patients.

59 s in treating HIV-1-infected individuals and AIDS patients.

60 n cause disseminated cutaneous infections in AIDS patients.

61 nsible for fatal opportunistic infections in AIDS patients.

62 ication sites outside the liver, at least in AIDS patients.

63 y help to explain the CD8+ T cell defects in AIDS patients.

64 s in treating HIV-1-infected individuals and AIDS patients.

65 served between healthy infected subjects and AIDS patients.

66 g more homogeneous in a subset of late-stage AIDS patients.

67 nsible for fatal opportunistic infections in AIDS patients.

68 sociated with body-cavity-based lymphomas in AIDS patients.

69 due to Cryptococcus neoformans are common in AIDS patients.

70 at occur frequently, but not exclusively, in AIDS patients.

71 tic disease from opportunistic infections in AIDS patients.

72 immunocompromised individuals, particularly AIDS patients.

73 idium parvum is an opportunistic pathogen in AIDS patients.

74 f short-term, postoperative mortality in HIV/AIDS patients.

75 aggressiveness of KS that occurs commonly in AIDS patients.

76 nd morbidity and mortality in transplant and AIDS patients.

77 ter during this period occurred in known HIV/AIDS patients.

78 ed to several malignancies commonly found in AIDS patients.

79 of short-term postoperative death among HIV/AIDS patients.

80 life-threatening opportunistic infection in AIDS patients.

81 ct short-term postoperative mortality in HIV/AIDS patients.

82 ated with greater morbidity and mortality in AIDS patients.

83 HAART alone may not circumvent this risk in AIDS patients.

84 nt of autologous stem cells were possible in AIDS patients.

85 tem in human immunodeficiency virus-infected AIDS patients.

86 and mortality world-wide, particularly among AIDS patients.

87 mphopenia limits the scale compared with non-AIDS patients.

88 th immunocompromised immune systems, such as AIDS patients.

89 tential inexpensive adjuvant therapy for HIV/AIDS patients.

90 ly prolonged the progression and survival of AIDS patients.

91 ble for increased morbidity and mortality in AIDS patients.

92 ndothelial cells commonly found in untreated AIDS patients.

93 dysfunction with devastating consequences in AIDS patients.

94 diseases, such as Pneumocystis pneumonia, in AIDS patients.

95 ly treat cryptosporiosis in some but not all AIDS patients.

96 mphoma and multicentric Castleman disease in AIDS patients.

97 osts and severe life-threatening diarrhea in AIDS patients.

98 ephalopathy (PML), which is commonly seen in AIDS patients.

99 dren and acquired immunodeficiency syndrome (AIDS) patients.

100 ation in acquired immunodeficiency syndrome (AIDS) patients.

101 umor in acquired immuno deficiency syndrome (AIDS) patients.

102 Among the AIDS patients, 75% were smokers, while 88.2% of the HIV

103 caused by Mycobacterium heckeshornense in an AIDS patient; a review of the literature is also include

104 and herpes simplex virus, HHV-6, and CMV in AIDS patients (accelerating the rate of human immunodefi

105 he cancer experience of New York State (NYS) AIDS patients aged 15-69 years who were diagnosed betwee

106 that has been linked to oral candidiasis in AIDS patients, although it has recently been isolated fr

107 maps of cortical gray-matter thickness in 26 AIDS patients and 14 healthy controls to establish the s

108 tion as recently infected occurred in 14% of AIDS patients and 29% (95% CI, 22, 38) of HAART subjects

109 , such as human immunodeficiency virus (HIV)/AIDS patients and children.

110 ings were demonstrated in the brain of adult AIDS patients and controls.

111 predict the SI phenotype were found in both AIDS patients and in patient 613; however, the distribut

112 ee life-threatening pathogens often found in AIDS patients and individuals whose immune system is imp

113 biliary infection is seen primarily in adult AIDS patients and is associated with development of AIDS

114 a major cause of opportunistic infection in AIDS patients and is difficult to manage using conventio

115 otential to be used in antiviral therapy for AIDS patients and might complement other gene-based stra

116 bular disease that is increasingly common in AIDS patients and one of the leading causes of end stage

117 e reviewed published case reports on HIV and AIDS patients and organ transplant recipients with sarco

118 istic fungal pathogen that primarily affects AIDS patients and patients undergoing immunosuppressive

119 improvement in immune function in pediatric AIDS patients and that the effect of suppressive treatme

120 tumour occurring most commonly in untreated AIDS patients and the leading cancer of men in certain p

121 n herpesvirus 8) is a significant problem in AIDS patients and transplant recipients, and clinical ma

122 ion (EBV, HHV-8) is a significant problem in AIDS patients and transplant recipients, and clinical ma

123 in immunocompromised individuals, including AIDS patients and transplant recipients.

124 quency of circulating CCR5(+) lymphocytes in AIDS patients and with a decline in CD4 lymphocyte numbe

125 th substantial morbidity and mortality among AIDS patients and young children.

126 of Kaposi's sarcoma and B cell neoplasms in AIDS patients, and a closely related primate virus, rhes

127 lopment, KS is the most frequent neoplasm in AIDS patients, and AIDS-KS is recognized as a particular

128 e most prevalent opportunistic infections in AIDS patients, and neither prophylaxis nor treatment aga

129 milar to most of those noted in the brain of AIDS patients, and provide the first evidence in the con

130 prognostic information about CMV disease in AIDS patients, and valaciclovir showed activity as both

131 fecting Acquired Immune Deficiency Syndrome (AIDS) patients, and more effective therapeutics for it a

132 However, levels of beta-chemokines in AIDS patients are comparable to and can exceed levels in

133 Of these, AIDS patients are particularly vulnerable to infection b

134 (KS) skin lesions found in both AIDS and non-AIDS patients are universally associated with infection

135 em for solid-organ transplant recipients and AIDS patients as well.

136 in post-mortem CNS tissues from donor neuro-AIDS patients, as determined by fluorescence resonance e

137 thods of cytomegalovirus (CMV) detection for AIDS patients at risk for CMV retinitis.

138 is superior to culture for identification of AIDS patients at risk for HCMV disease, and quantitation

139 variants were found only in the PBMC of one AIDS patient but only in the NSMC of the other, while th

140 infection in vitro and in brain tissue from AIDS patients, but the apoptotic stimuli have not been i

141 ole of beta-chemokines in nonprogressors and AIDS patients by examination of beta-chemokine productio

142 ry linkage analysis evaluates cancer risk in AIDS patients by sex and risk factors and adds evidence

143 Microsporidium infections in AIDS patients can be quantified by counting spores in st

144 atients with Salmonella (NTS) infection, and AIDS patients can have episodes of Salmonella enteritis

145 tis, the most common ophthalmic infection of AIDS patients, causes blindness if left untreated.

146 duals with compromised immunity, such as HIV/AIDS patients, causing life-threatening meningoencephali

147 tric growth factor-dependent tumor common in AIDS patients characterized histopathologically by spind

148 In CSF specimens from AIDS patients, CMV was detected in 10 of 58 (17%) specim

149 idization to be expressed in the brain of an AIDS patient coinfected with C. neoformans.

150 f the hyperplastic B cell LPDs manifested in AIDS patients coinfected with KSHV.

151 tudies investigated whether neutrophils from AIDS patients could inhibit the growth of M. avium in vi

152 ccus neoformans causes serious infections in AIDS patients, cryptococcosis in immunologically immatur

153 ponses (e.g., lung transplant recipients and AIDS patients), cytomegalovirus (CMV) infection causes s

154 er 1,000,000 infections and one third of all AIDS patient deaths.

155 IPC numbers were markedly reduced in AIDS patients developing opportunistic infections and ca

156 ssion of chemokines in intestinal tissues of AIDS patients during active Cryptosporidium infection an

157 reas six of nine brain samples obtained from AIDS patients exhibited reduced RON protein.

158 ral therapy (HAART), the challenges that HIV/AIDS patients face with regard to ocular complications h

159 ency virus type 1 (HIV-1) representing eight AIDS patients from Botswana were sequenced and analyzed

160 uals, typically human immunodeficiency virus/AIDS patients from developing countries.

161 y analyzed Salmonella (NTS) infection in HIV/AIDS patients from June 2003 until December 2009 at the

162 atients, 9 of whom had AIDS, including all 5 AIDS patients from one floor of a nursing home affiliate

163 e of AIDS (7%), and approximately 50% of non-AIDS patients had upper-lobe cavitary disease and 50% ha

164 the incidence of Kaposi's sarcoma (KS) among AIDS patients has declined both nationwide and in King C

165 progenitor phenotype have been isolated from AIDS patients has led to speculation that mast cells may

166 inal tract and cause disseminated disease in AIDS patients has not been epidemiologically linked to M

167 tis, the most common ophthalmic infection of AIDS patients, has been modeled in BALB/c mice infected

168 Neuropathological abnormalities in AIDS patients have been associated with perivascular HIV

169 and the appearance of anti-GM3 antibodies in AIDS patients have been reported earlier.

170 Neutrophils isolated from AIDS patients have demonstrated improved growth inhibiti

171 acquired by ingestion, and a large number of AIDS patients have M. avium in their intestinal tracts.

172 pressed transplant recipients and late-stage AIDS patients, HCMV infection and reactivation can resul

173 antiretroviral drugs successfully treat HIV/AIDS patients; however, drug resistance problems make th

174 oting the aggressive manifestations of KS in AIDS patients; however, the pathogenesis underlying AIDS

175 cobacterium avium was isolated from an adult AIDS patient in Southern California in 1983.

176 Because of the large proportion of AIDS patients in South Africa, we tested the generality

177 Thus, isolates from symptomatic AIDS patients in the United States can display the same

178 nce of cryptococcal infection among advanced AIDS patients in the United States was high and above th

179 m avium is a major opportunistic pathogen of AIDS patients in the United States.

180 diatric acquired immune deficiency syndrome (AIDS) patients in relation to neuropathological conseque

181 similar acquired immunodeficiency syndrome (AIDS) patients in the United States, an area predominant

182 e1, and Tie2 mRNAs in biopsies of KS from 12 AIDS patients, in biopsies of cutaneous angiosarcoma fro

183 le decline in the morbidity and mortality in AIDS patients, inadequately low delivery of anti-retrovi

184 Under these conditions the survival rate of AIDS patients is reduced significantly.

185 ata regarding ocular complications among HIV/AIDS patients is scarce.

186 A critical question for AIDS patients is whether treatment with antiretroviral d

187 KS), the most frequent malignancy afflicting AIDS patients, is characterized by spindle cell formatio

188 ue to have 5-fold greater mortality than non-AIDS patients, it is unclear whether HCV infection incre

189 By contrast, in AIDS patients lacking effector cells, CXCL10 may contrib

190 T) remains the most effective method to save AIDS patients' lives.

191 ether, these results suggest that, among non-AIDS patients, M. intracellulare is more pathogenic and

192 (n = 134) and subjects with low CD4 counts (AIDS patients [n = 140]) was used to measure the false-r

193 Chemotherapy depletes T cells in AIDS patients on HAART, but preexisting lymphopenia limi

194 dies and the observed clinical resistance of AIDS patients on long-term AZT therapy.

195 ponse could serve as an important barrier in AIDS patients or other individuals with compromised CD4+

196 or can reactivate to cause acute diseases in AIDS patients or patients receiving immunosuppressive th

197 posi's sarcoma, another common malignancy in AIDS patients, or opportunistic infections.

198 ing chronic diarrhea and systemic disease in AIDS patients, organ transplant recipients, travelers, a

199 denal aspirate or biopsy specimens from five AIDS patients originating from California, Colorado, and

200 transcriptase (RT) from approximately 40,000 AIDS patient plasma samples sequenced by Specialty Labor

201 t predict HIV (human immunodeficiency virus)/AIDS patient postoperative mortality have remained poorl

202 ol the persistent infection, which arises in AIDS patients principally because of an erosion of the C

203 In contrast, CD4+ clones from AIDS patients produced no RANTES and little or no MIP-1a

204 ida albicans colonies from each infection in AIDS patients receiving fluconazole therapy for orophary

205 Eleven AIDS patients receiving HAART with healed CMV retinitis

206 uppressed hosts, including patients with HIV/AIDS, patients receiving immunosuppressing drugs, and so

207 Examination of KS biopsies from AIDS patients revealed active Akt as a prominent feature

208 Like epidemic KS in AIDS patients, RF is highly associated with an immunodef

209 nes from nonprogressors and CD8+ clones from AIDS patients secreted high levels of RANTES, MIP1alpha,

210 ethnic minority, heterosexually infected and AIDS patients should be combined with immunologic monito

211 K cells obtained from both normal donors and AIDS patients showed potent (routinely > or = 90%) suppr

212 Certain lymphomas in AIDS patients, such as primary effusion lymphoma (PEL),

213 As many as 13% of all AIDS patients suffer a life-threatening cryptococcal inf

214 Many AIDS patients suffer from cognitive impairments includin

215 Forty percent of AIDS patients suffer from neurological symptoms, but the

216 ognitive disorders (HAND), with about 30% of AIDS patients suffering severe HIV-associated dementias

217 All had responded to the AIDS Patient Survey; 643 had been tested confidentially

218 ly reported the isolation of viruses from an AIDS patient that were able to infect CD8(+) cells indep

219 d Mycobacterium avium infection is common in AIDS patients that do not receive anti-AIDS therapy and

220 nfluenza-specific CD4(+) T-cell responses in AIDS patients that was also present in asymptomatic HIV-

221 certain circumstances (e.g., in neonatals or AIDS patients), the infection becomes disseminated, ofte

222 In AIDS patients, the absolute number of CD8+ T lymphocytes

223 In AIDS patients, the functional defect is more severe, sin

224 both B and C strains are represented in U.S. AIDS patients, the majority (70 to 80%) of samples from

225 In AIDS patients, the onset of MAC bacteremia is associated

226 ffective in decreasing active viral loads in AIDS patients, the persistence of latent viral reservoir

227 rates in acquired immunodeficiency syndrome (AIDS) patients, the cancer experience of New York State

228 -CSF (2000 U/mL) stimulated neutrophils from AIDS patients to significantly inhibit M. avium growth.

229 hly active antiretroviral therapy) may allow AIDS patients to undergo an immune recovery that allows

230 Thus, neutrophils isolated from AIDS patients treated with G-CSF demonstrated a signific

231 f C. neoformans var. neoformans from Ugandan AIDS patients was tested by both methods.

232 um avium, a common opportunistic pathogen in AIDS patients, was shown to result in increased tissue e

233 ted States and BCBLs appear predominantly in AIDS patients, we examined whether LANA is able to regul

234 ples from some of the earliest known Haitian AIDS patients, we find that subtype B likely moved from

235 rative mortality risk stratification for HIV/AIDS patients, we have found that several clinical and l

236 episodes of Pneumocystis pneumonia (PCP) in AIDS patients, we tested the effect of nicotine treatmen

237 that confer multidrug resistance (mdr) in an AIDS patient were tested for interaction in yeast.

238 rates for sequential specimens obtained from AIDS patients were comparable to those for non-AIDS pati

239 AIDS patients were followed with urine and blood specime

240 ceptible to ADA replication, but clones from AIDS patients were highly infectable.

241 om human immunodeficiency virus-negative and AIDS patients were incubated with media, granulocyte col

242 ic, contrasting with previous data for neuro-AIDS patients where immune tissue Envs mediated a range

243 the bystander effect observed in the LNs of AIDS patients, whereby cells not making virus are dying.

244 sion inhibitor approved for treatment of HIV/AIDS patients who fail to respond to the current antiret

245 itor that is being used for treatment of HIV/AIDS patients who have failed to respond to current anti

246 In AIDS patients who present with an oral neoplasm, Kaposi

247 We retrospectively reviewed all HIV/AIDS patients who underwent surgical procedures in Briti

248 terium avium is an opportunistic pathogen in AIDS patients, who acquire the infection mainly through

249 em in immunocompromised individuals, such as AIDS patients, who lack effective CD4 T helper cell func

250 An estimated 38 to 45 percent of AIDS patients whose disease progresses rapidly (less tha

251 ecently obtained nucleotide sequence from an AIDS patient with a multidrug-resistant virus.

252 herefore used these agents as therapy for an AIDS patient with PEL.

253 PBMC from AIDS patients with <200 CD4 cells/mL had significantly l

254 ion transfer MR imaging were performed in 21 AIDS patients with 42 areas of white matter hyperintensi

255 Organization recommends routinely screening AIDS patients with a CD4 count </=100 cells/microL for c

256 In biopsies from AIDS patients with active cryptosporidiosis, four chemok

257 o combat HIV-1-induced neuronal apoptosis in AIDS patients with ADC.

258 the secondary sclerosing cholangitis seen in AIDS patients with biliary cryptosporidiosis.

259 ndence on CCR5 and CD4 in the brains of some AIDS patients with central nervous system disease and su

260 ic and clinical aspects of CMV infections in AIDS patients with CMV retinitis.

261 -1 suggests that the neuronal damage seen in AIDS patients with cognitive disorders is caused indirec

262 he scant inflammatory response often seen in AIDS patients with cryptococcosis and candidiasis is not

263 vel of CXCL10 was significantly increased in AIDS patients with cryptosporidiosis compared to the lev

264 oridiosis or in normal volunteers (median in AIDS patients with cryptosporidiosis, 508 pg/mg protein,

265 vitritis, IRV), which causes vision loss in AIDS patients with cytomegalovirus (CMV) retinitis, who

266 viruses from brain tissue samples from three AIDS patients with dementia and HIV-1 encephalitis and a

267 , blood, spleen, and lymph node samples from AIDS patients with dementia and HIV-1 encephalitis.

268 nfection and its elevation in brain cells of AIDS patients with dementia.

269 genotype and enteric infection in 72 Zambian AIDS patients with diarrhea, immunofluorescence analysis

270 viduals who are immunocompromised, including AIDS patients with few CD4(+) T cells, are at increased

271 Breakdown of the BBB is commonly seen in AIDS patients with HIV-1-associated dementia despite the

272 nt at a high frequency in brain tissues from AIDS patients with HIV-associated dementia (HAD).

273 ples from human immunodeficiency virus (HIV)/AIDS patients with intestinal microsporidiosis collected

274 rated that microsporidian coinfection in HIV/AIDS patients with intestinal microsporidiosis is not un

275 elop more effective therapeutic vaccines for AIDS patients with low CD4(+) T cell counts.

276 as detected, the administration of GM-CSF to AIDS patients with MAC bacteremia resulted in activation

277 Eight AIDS patients with Mycobacterium avium complex (MAC) bac

278 been detected in the cerebrospinal fluid of AIDS patients with neurological disorders.

279 and neuronal damage observed in the brain of AIDS patients with neurological dysfunctions.

280 In post-mortem brain tissues from AIDS patients with opportunistic infections, but without

281 After HAART, AIDS patients with opportunistic intestinal pathogens di

282 ropteroate synthase (DHPS) gene mutations in AIDS patients with P. carinii pneumonia (PCP) are affect

283 The P. carinii DHPS genes from 97 AIDS patients with PCP between 1991 and 1999 from 4 medi

284 s been associated with improved survival for AIDS patients with PKS.

285 Predictors of long-term survival in AIDS patients with PML include PML as the heralding mani

286 progressive infection with this pathogen of AIDS patients with reduced CD4(+) T-cell numbers.

287 y predicted the clinical presentation of HIV/AIDS patients with Salmonella (NTS) infection, and AIDS

288 e of particular use in the monitoring of non-AIDS patients with the acute and disseminated forms of t

289 In contrast, antigen titers in four of six AIDS patients with the disseminated form of the disease

290 from 15 acquired immunodeficiency syndrome (AIDS) patients with biopsy-proven PML were analyzed by s

291 comes of acquired immunodeficiency syndrome (AIDS) patients with Cytomegalovirus retinitis (CMVR) -re

292 ompared to 111 pg/mg and 72 pg/mg protein in AIDS patients without cryptosporidiosis and in normal vo

293 h cryptosporidiosis compared to the level in AIDS patients without cryptosporidiosis or in normal vol

294 In this clinical study, 30 AIDS patients without M. avium infection were randomized

295 In this study, 30 AIDS patients without Mycobacterium avium infection were

296 ts of Africa and is the most common tumor of AIDS patients world-wide.

297 osi's sarcoma (KS), the most common tumor of AIDS patients worldwide.

298 i's sarcoma (KS) is the most common tumor of AIDS patients worldwide.

299 in immunocompromised cancer, transplant, and AIDS patients, yet little is known about how persistent

300 uberculosis is the leading cause of death in AIDS patients, yet the current tuberculosis vaccine, Myc